Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: An investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy

Liver

Volumn 22, Issue 5, 2002, Pages 404-412

  Constantini, Patricia K ^a,b   Wawrzynowicz Syczewska, Marta ^a,c   Clare, Michael ^a   Boron Kaczmarska, Anna ^c   McFarlane, Ian G ^a   Cramp, Mathew E ^a,d   Donaldson, Peter T ^a,e  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Hepatitis C virus; Interferon gamma; Interleukin 1; Interleukin 10; Tumour necrosis factor alpha

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLEARANCE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC CODE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIGENE FAMILY; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION;

ADOLESCENT; ADULT; AGED; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-1; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIREMIA;

EID: 0036809525     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2002.01553.x     Document Type: Article

References (44)

1. VAN DER POEL C L, CUYPERS H T, REESINK H W. Hepatitis C virus six years on. Lancet 1994; 344: 1475-9.
2. ALTER M J, MARGOLIS H S, KRAWCZYNSKI K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-905.
3. DONALDSON P T. The inter-relationship between hepatitis C virus and HLA. Eur J Clin Invest 1999; 29: 280-3.
4. THIO C L, THOMAS D L, CARRINGTON M. Chronic viral hepatitis and the human genome. Hepatology 2000; 31: 819-27.
5. DIEPOLER H M, SCHOLZ S, PAPE G R. Influence of HLA on outcome of hepatitis C virus infection. Lancet 1999; 354: 2094-5.
6. NAUOMOV N. Hepatitis C virus specific CD4+ T cells: do they help or damage? Gastroenterology 1999; 117: 1012-4.
7. CRAMP M E, ROSSOL S, CHOKSHI P, CARUCCI P, WILLIAMS R, NAOUMOV N V. Hepatitis C virus-specific T cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 29: 346-55.
8. ALRIC L, FORT M, IZOPET J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.
9. CRAMP M E, CARUCCI P, UNDERHILL J, NAOUMOV N V, WILLIAMS R, DONALDSON P T. Association between HLA class II genotype and spontaneous clearance of HCV infection. J Hepatol 1998; 29: 207-13.
10. MINTON E J, SMILLIE D, NEAL K R, IRVING W L, UNDERWOOD C, JAMES V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998; 178: 39-44.
11. THURSZ M, YALLOP R, GOLDIN R, TREPO C, THOMAS H C FOR THE HENCORE GROUP. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119-24.
12. ZAVAGLIA C, MARTINETTI M, SILINI E, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28: 1-7.
13. MANGIA A, GENTILE R, CASCAVILLA I, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30: 984-9.
14. HOHLER T, KRUGER A, GERKEN G, SCHNEIDER P M, MEYERZUM-BUSCHENFELDE K, RITTNER C. Tumour necrosis factor-alpha promoter polymorphism at position-238 is associated with chronic active hepatitis C virus infection. J Med Virol 1998; 54: 173-7.
15. ASTI M, MARTINETTI M, ZAVAGLIA C, et al. Human leucocyte antigen class II and class III alleles and severity of hepatitis C virus - related chronic liver disease. Hepatology 1999; 29: 1272-9.
16. YEE L J, TANG J, HERRERA J, KASLOW R A, VAN LEEUWEN D J. Tumour necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatits C virus infection. Genes Immunity 2000; 1: 386-90.
17. EDWARDS-SMITH C J, JOHNSSON J R, PURDIE D M, BANSAL A, SHORTHOUSE C, POWELL E E. Interleukin-10 promoter polymorphism predicts initial response of hepatitis C virus to interferon alfa. Hepatology 1999; 30: 526-78.
18. POWELL E E, EDWARDS-SMITH C J, HAY J L, et al. Host factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
19. YEE L J, TANG J, GIBSON A W, KIMBERLY R, VAN LEEUWEN D J, KASLOW R A. Interleukin 10 polymorphism as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-12.
20. MANSFIELD J C, HOLDEN H, TARLOW J K, et al. Novel genetic association between ulcerative colitis and the anti-inflamatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-42.
21. DINARELLO C A. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
22. POCIOT F, MOLVIG J, WOGENSEN L, WORSAAE H, NERUP J. A Taq1 polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
23. DANIS V A, MILLINGTON M, HYLAND V J, GRENNANI D. Cytokine production by normal human macrophages: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1 Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
24. SANTTILA S, SAVINAINEN K, HURME M. Presence of the IL-1RA allele; 2 (IL1RN:*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47: 195-8.
25. HURME M, SANTTILA S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1B genes. Eur J Inummol 1998; 28: 2598-602.
26. MCDOWELL T L, SYMONS J A, PLOSKI R, FΦRREØ, DUFF G W. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism. Arthritis Rheum 1995; 38: 221-8.
27. EL-OMAR E M, CARRINGTON M, CHOW W-H, et al. Interleukin 1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
28. DONALDSON P, AGARWAL K, CRAGGS A, CRAIG W, JAMES O, JONES D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001; 48: 397-402.
29. ISHAK K, BAPTISTA A, BIANCHI L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
30. BIOQUE G, CRUSIUS J B A, KOUTROUBAKIS I, et al. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379-83.
31. COOKSON S, CONSTANTINI P K, CLARE M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851-6.
32. TARLOW J K, BLAKEMORE A I, LENNARD A, et al. Polymorphism in the human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-4.
33. TURNER D M, WILLIAMS D M, SANKARAN D, LAZARUS M, SINNOTT P J, HUTCHINSON I V. An investigation of polymorphism in the interleukin-10 promoter. Eur J Immunogenet 1997; 24: 1-8.
34. MCGUIRE W, HILL A V S, ALLSOPP C E M, GREENWOOD B M, KWIATKOVSKI D. Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-11.
35. D'ALFONSO S, RICHIARDI P M. A polymorphic variation in a putative regulation box of the TNFA promotor region. Immunogenet 1994; 39: 150-4.
36. SVEJGAARD A, RYDER L P. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994; 43: 18-27.
37. CAMPBELL R D, TROWSDALE J. A map of the human major histocompatibility complex. Immunol Today 1997; 18: 43.
38. WILSON A G, SYMONS J A, MCDOWELL T L, MCDEVITT H O, DUFF G W. Effects of a polymorphism in human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
39. STUBER F, UDALOVA I A, BOOK M, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46: 42-50.
40. WESTENDORP R G J, LANGERMANS J A M, HUIZINGA T W J, ELOUALI A H, VERWEIJ C L. Boomsma D I, Vandenbrouke J P. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-3.
41. LOUIS E, FRANCHIMONT D, PIRON A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-a production in lippopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-6.
42. ROTHMAN K J. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.
43. ANONYMOUS. Freely associating. Nature Genet 1999; 22: 1-2.
44. ABRAMS J R, LEBWOHL M G, GUZZO C A, JAGASOTHY B V, GOLDFARB M T, GOFFE B S. CTLA-4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52.